U.S. Markets open in 6 hrs 6 mins
  • S&P Futures

    4,399.00
    +5.25 (+0.12%)
     
  • Dow Futures

    34,925.00
    +91.00 (+0.26%)
     
  • Nasdaq Futures

    15,007.75
    -3.75 (-0.02%)
     
  • Russell 2000 Futures

    2,233.60
    +12.90 (+0.58%)
     
  • Crude Oil

    73.01
    +0.62 (+0.86%)
     
  • Gold

    1,818.30
    +18.60 (+1.03%)
     
  • Silver

    25.45
    +0.57 (+2.30%)
     
  • EUR/USD

    1.1871
    +0.0024 (+0.2018%)
     
  • 10-Yr Bond

    1.2610
    0.0000 (0.00%)
     
  • Vix

    18.31
    -1.05 (-5.42%)
     
  • GBP/USD

    1.3949
    +0.0040 (+0.2873%)
     
  • USD/JPY

    109.8240
    -0.0860 (-0.0783%)
     
  • BTC-USD

    40,041.27
    +326.10 (+0.82%)
     
  • CMC Crypto 200

    936.61
    +6.68 (+0.72%)
     
  • FTSE 100

    7,052.25
    +35.62 (+0.51%)
     
  • Nikkei 225

    27,782.42
    +200.76 (+0.73%)
     

Zynerba's Zygel Improves Sleep In Children With Severe Epilepsies

·1 min read
  • Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) presents sleep data from an open-label Phase 2 trial evaluating Zygel for developmental & epileptic encephalopathies (DEE) and autism spectrum disorder (ASD).

  • Results were presented at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting.

  • The treatment was associated with improved sleep in children with clinically significant sleep disorders at baseline.

  • Furthermore, the children with both DEE and autism spectrum disorder (ASD) showed more wide-ranging sleep benefits than those with DEE alone.

  • In patients with ASD (n=5), improvements compared to baseline were observed over the 26-week study period in sleep breathing, sleep-wake transition, and the total sleep disturbance scale for children.

  • In patients without ASD (n=11), improvement was seen in initiating and maintaining sleep.

  • Zygel was well tolerated. Most treatment-emergent adverse events were characterized as mild or moderate.

  • Over the 26-week study period, 60.4% of participants had more than one related adverse event, with 93% mild/moderate severity.

  • Price Action: ZYNE shares are up 2.95% at $5.58 during the market session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.